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Early intensive care for severe acute pancreatitis is essential for improving SAP mortality rates. However, intensive therapies for
SAP are often delayed because there is no ideal way to accurately evaluate severity in the early stages. Currently, perfusion CT
has been shown useful to predict prognosis of SAP in the early stage. In this presented paper, we would like to review the clinical
usefulness and limitations of perfusion CT for evaluation of local and systemic complications in early stage of SAP.
1.Introduction
Severe acute pancreatitis (SAP) is a fatal disease [1]. The
Atlanta Symposium criteria for the severity of acute pan-
creatitis deﬁne SAP as acute pancreatitis with local com-
plications (pancreatic necrosis, abscess, and pseudocysts)
and/or with systemic complications (organ failure, dissem-
inated intravascular coagulation, and severe metabolic dis-
turbances)[2](Figure 1).Bothacutenecrotizingpancreatitis
(ANP) and multiple-organ failure (MOF) have been shown
to be signiﬁcant prognostic factors [3–6]. Mortality rates for
SAP patients developing ANP and MOF are 32% and 30%,
respectively [7]. Early intensive care for SAP is essential for
improving SAP mortality rates [8–10]. However, intensive
therapies for SAP are often delayed because there is no ideal
waytoaccuratelyevaluateseverityintheearlystages[11–13].
Perfusion CT has been used for evaluation of various
pancreatic diseases [14–22]. Perfusion CT has been shown
useful to predict prognosis of SAP in the early stage [17, 18].
In this presented paper, we would like to review the clinical
usefulness and limitations of perfusion CT for evaluation of
local and systemic complications in early stage of SAP.
2. PerfusionCT Technique
Previously published perfusion CT protocols are summa-
rized in Table 1. Multidetector CT (MDCT) is essential for
performing perfusion CT of pancreas. With a 4–64 slice
MDCT scanner, perfusion CT scans are obtained with the
patient in a stationary position. The craniocaudal CT scan
c o v e r a g ei sl i m i t e dt o2 0t o3 2 m m( 4s l i c e so f5t o8 m m
thickness). Therefore, scan location must be carefully chosen
to cover as much of the pancreas as possible as it is often
diﬃcult to cover the entire pancreas. Since most pancreatic
necrosis occurs in the neck region, it is probably uncommon
to exclude the area of necrosis due to the scanning coverage
limitation. With the use of a recently developed 256–
320-slice MDCT scanners [19], craniocaudal coverage has
increased to 80–160mm. Alternative way to increase the
craniocaudal coverage is by using the so-called shuttle or
toggle mode. In this mode, similar to conventional CT scans,
patient table moves back and forth as the multiple scans are
performed.
First, noncontrast transaxial images of the upper
abdomen are obtained using low-dose technique. This scan
is performed to localize the pancreas, and it determines the
scan range of the perfusion CT.
Perfusion CT is performed after a bolus injection of
intravenous contrast material. Unlike conventional CT, the
perfusion CT requires smaller dose (40–50mL) of contrast
material injected at a high rate (4–10mL/sec). Higher con-
centrationofcontrastmaterial(350–370mgI/kg)ispreferred
[23–25].2 International Journal of Inﬂammation
Perfusion CT images are obtained multiple times
through the pancreas. In most of previous reports, scan
interval ranges from 0.5 to 1.5 second, and the scan duration
ranges from 30 to 150 seconds, respectively (Table 1).
Total scan duration necessary for calculation of perfusion
parameters may depend on the algorithm used. For example,
maximum slope method needs shorter duration scan time
thanthedeconvolutionmethod[14,19,26].Becausethescan
duration is long, the scans are usually performed under free
breathing.
Perfusion CT scan is obtained at a low tube current
(mAs) to reduce radiation dose. At 120kV, mAs of 100 is
commonly used. There is increased interest in the use of
low tube voltage setting, as it reduces radiation dose and
improves iodine contrast material conspicuity. In a smaller
patient, the use of 100kV or 80kV is recommended. In a
larger patient, the use of low-kV scan may result in noisy
images due to photon deﬁciency.
2.1. Radiation Dose and Scan Parameters. Radiation dose is
dependent on the tube current (mAs), tube voltage (kV),
numberofscans,andscancoverage[29].Tubecurrent(mAs)
and tube voltage (kV) are largely dictated by the patient size
to maintain adequate image quality. Radiation dose should
bekeptaslowasreasonablyachievable(ALARA)byreducing
the scanning parameter settings but achieving image dataset
adequate for calculating CT perfusion parameters [27, 30].
Further study is necessary to optimize the scanning protocol.
From a European study, the eﬀective dose of pancreatic
perfusion CT was 3.54mSv with 90KV, 100mAs, and
40 scans [17]. A study from Japan reported that mean
radiation dose of pancreatic perfusion CT was approxi-
mately 204.8mGy·cm (dose-length product (DLPw)), 3.07
mSv (eﬀective dose), and 64mGy (CT dose index volume
(CTDIvol)) with 80kV, 60mAs, and 106 scans [27]. In the
national survey, the radiation exposure of a single-phase
abdominal CT was 13–25 mGy (CTDIvol) [31]. Therefore,
the radiation dose of perfusion CT is slightly higher than
that of biphasic (two phase), which is commonly used for
pancreatic or liver imaging. Average abdominal transverse
diameter of the Japanese patients in our experience was
32cm, while transverse diameters of patients in the Unites
States are usually larger [32]. Therefore, the radiation dose
will likely be higher in the western countries
2.2. Perfusion CT Data Analysis. Pancreatic perfusion CT
image data are analyzed by using perfusion CT analysis
software. There are various perfusion algorithms to calculate
perfusion parameters. Maximum slope method, deconvolu-
tion method, single-compartment method, and the Patlak
method are commonly used perfusion algorithms. Which
perfusion best suits in the evaluation of SAP is yet to be
determined. As diﬀerent perfusion algorithms are suited for
diﬀerent disease processes and require diﬀerent scanning
protocol, determination of scanning protocol and perfusion
algorithms should be considered together. For example,
maximum slope method may require shorter scanning
duration, but higher rate of contrast injection is required,
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Figure 1: Schema of complications of severe acute pancreatitis.
WOPN: walled-oﬀ pancreatic necrosis.
while deconvolution method may require longer scanning
duration but slower rate of contrast injection rate [14, 26].
The software requires placement of small regions of
interest (ROI) on an artery to generate arterial input func-
tion. Venous outﬂow function is required in deconvolution
method. This process is required because the computer
algorithm compares the shape and height of the time-
density curve of each pixel of the pancreatic CT time series
with shape and height of the arterial and/or venous time-
density curves to calculate pancreatic perfusion parameters.
Calculated pancreatic perfusion parameters are displayed
using color maps [14].
3. Perfusion CT for PredictingDevelopment
of PancreaticNecrosisinthe Early
Stage of Severe Acute Pancreatitis
Development of pancreatic necrosis is the critical event
of acute pancreatitis that determines the prognosis of the
patients. The overall mortality rate of acute pancreatitis
is reported to be between 2.1% and 9.2% worldwide [1].
Pancreatic necrosis occurs in 10–15% of patients with SAP,
with a mortality rate of 23% [1]. This rate is nearly twice that
forpatientswithSAPwhodonotdeveloppancreaticnecrosis
(i.e., 11%) [1].
There is a report that dynamic contrast-enhanced CT is
moreaccuratethaneithertheRansoncriteriaforpancreatitis
mortality or the APACHE II scoring system in predicting
the development of pancreatic necrosis [33]. However, the
accuracy of contrast-enhanced CT in predicting necrosis
at an early stage of SAP is not satisfactory [34]. The
United Kingdom guidelines for the management of acute
pancreatitis, the most popular clinical guideline of acute
pancreatitis, recommendsthat contrast-enhancedCT should
be performed at day 3 or later after onset of SAP because of
its low sensitivity of CT [11].
In ourexperience,perfusionCT performedwithin 3days
of onset of symptoms had a sensitivity and speciﬁcity of
100% and 95.3% for predicting development of pancreatic
necrosis [18]. The area of necrosis was depicted as areaInternational Journal of Inﬂammation 3
Table 1: Scanning protocols of pancreatic perfusion CT.
Authors Disease CT
The
number of
detector
kv mA Images Contrast matter
Duration
time (sec) Algorithm
Injection rate
(mL/sec) Amount
Miles [25]
— — — — 50–100 60 4–7 40mL 60 Deconvolution
100–250 15 7–10 50mL 45 Compartment
100–250 6 4 100mL 120 Patlak plot
Tsushima and
kusano [15] Normal S 1 — — 19 5 40mL 85 Maximum slope
Abe et al. [16] PC G 1 120 60 — 5 0.5mL/kg 40 Deconvolution
Bize et al. [17] AP P 16 90 100 40 5 40mL 40 Maximum slope
Tsuji et al. [18] AP T 16/64 120 30–50 30–48 4 40mL 33–48 Deconvolution
Tsuji et al. [27] AP/NET T 64 80 40 106 4 40mL 54 Deconvolution
Sheiman and
Stick [28] Normal G 64 100 80 30 4 40mL 90 Compartment
d’Assignies et al.
[20] NET G 64 100 100 70 4 40mL 150 Compartment
Park et al. [21] PC S 64 100 100 30 5 50mL 30 Patlak plot
Kandel et al.
[19] PC T 320 100 45 19 8 60mL 80 Maximum slope
PC: pancreatic cancer; AP: acute pancreatitis; NET: neuroendocrine tumor; S: Siemens; G: GE Health care; P: Philipse; T: Toshiba.
of pancreatic blood ﬂow decreased by more than 19.3%
of surrounding pancreatic parenchyma. The area of perfu-
sion defect was commonly diagnosed by using pancreatic
blood ﬂow. The perfusion defects detected by perfusion CT
reﬂected ischemia which was produced by vasospasms of the
intrapancreatic arteries [35, 36].
4. Perfusion CT for EvaluatingSystemic
BloodFlow
Perfusion CT could be a useful tool to evaluate abnormal
systemic circulation in early stage of SAP. Recent study by
Whitcomb et al. showed that elevated serum angiopoietin-2
(Ang-2) on admission is predictive of persistent organ failure
in patients with sap [37]. Ang-2 is produced by damaged
vessels and increases vascular permeability [38]. In our
study, elevated serum Ang-2 is related with hyperdynamic
state of systemic circulation [22]. In this study, perfusion
CT parameter (τ) was calculated using single-compartment
model [28, 39]. τ is a measure of the mean transit time of
contrast material from upper abdominal aorta to pancreas;
thus, this could be considered a surrogate of systemic
circulation with a lower value indicating hyperdynamic
state of systemic circulation [28]. In the result, signiﬁcant
correlation was found between τ and serum Ang-2 levels
(P<0.05); higher serum Ang-2 levels were associated with
lower τ values (hyperdynamic state of systemic circulation).
Hepatic circulation abnormality has been reported in
patients with SAP using Perfusion CT [40]. They reported
that hepatic arterial perfusion is increased in the early stage
of SAP as measured on dual-input maximum slope method.
5.ClinicalUtilityofPancreatic
Perfusion CT
Early diagnosis of pancreatic necrosis is very important in
the treatment of patients with SAP. Current methods to
predict early pancreatic necrosis or SAP is not satisfactory
[11–13]. Perfusion CT is a promising technique that allows
accurate diagnosis of pancreatic necrosis. Early diagnosis
allows prompt clinical decision such as transferring patients
to ICU or institution of aggressive treatment such as antico-
agulation therapy [41], continuous regional arterial infusion
of antiprothrombin agent [8, 9], early ﬂuid resuscitation
[10], and molecular targeted therapy [42, 43].
6. Conclusion
Perfusion CT is a promising technique for diagnosis of local
and systemic complications of SAP at an early stage.
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